Skip to content
Equity Capital Market
  • Start Here
  • Research
    • LightPath Deal
    • Plug Power ATM
    • Standard Nuclear IPO
  • Latest
  • Stock Market
  • Market Education
  • Capital Markets
  • Federal Reserve & Rates
  • About
  • Contact

merck earnings

Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge

September 12, 2026May 1, 2026 by Bruno
Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge

Merck Q1 2026: $16.3B revenue beat, guidance raised. A $9B acquisition charge drove a GAAP loss, but Winrevair growth signals strong underlying fundamentals.

Categories Stock Market Tags drug stocks Q1 2026, keytruda, merck earnings, MRK stock, pharmaceutical stocks, stock market

Explore ECMSource

New here? Begin with our guide to the site, then explore the subjects that match what you want to understand.

  • Start Here
  • Market Education
  • Stock Market
  • Capital Markets
  • Federal Reserve & Rates

Recent Posts

  • McDonald’s Unveils $8.5B Plan and Low-50s Margin Goal
  • Qualified vs. Ordinary Dividends: Tax Rules Explained
  • Halozyme Inks $1.5B Convertible Debt Deal and Capped Calls
  • DoorDash Inks $131.5M NYC Delivery Worker Settlement
  • Treasury Bills: Discount Rate vs. Investment Yield Explained

About · Editorial Policy · Corrections · Disclaimer · Privacy · Contact

© 2026 Equity Capital Market • Built with GeneratePress